Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Leukemia

  Free Subscription


09.04.2018

1 Ann Hematol
2 Blood
2 BMC Cancer
1 Eur J Haematol
1 J Clin Oncol
1 J Pediatr Hematol Oncol
7 Leuk Lymphoma
2 Leuk Res
1 N Engl J Med


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Hematol

  1. MARHALL A, Heidel F, Fischer T, Ronnstrand L, et al
    Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
    Ann Hematol. 2018;97:773-780.
    PubMed     Text format     Abstract available


    Blood

  2. WANG F, Demir S, Gehringer F, Osswald CD, et al
    Tight regulation of FOXO1 is essential for maintenance of B-cell precursor acute lymphoblastic leukemia.
    Blood. 2018 Apr 5. pii: blood-2017-10-813576. doi: 10.1182/blood-2017-10-813576.
    PubMed     Text format     Abstract available

  3. STATLER A, Othus M, Erba HP, Chauncey TR, et al
    Comparable Outcomes of Patients Eligible versus Ineligible for SWOG Leukemia Studies.
    Blood. 2018 Apr 4. pii: blood-2018-01-826693. doi: 10.1182/blood-2018-01-826693.
    PubMed     Text format     Abstract available


    BMC Cancer

  4. ZHANG L, Zou Y, Chen Y, Guo Y, et al
    Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial.
    BMC Cancer. 2018;18:374.
    PubMed     Text format     Abstract available

  5. ATALLAH E, Schiffer CA, Weinfurt KP, Zhang MJ, et al
    Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.
    BMC Cancer. 2018;18:359.
    PubMed     Text format     Abstract available


    Eur J Haematol

  6. TIEN FM, Hou HA, Tsai CH, Tang JL, et al
    Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor-risk factor in de novo acute myeloid leukemia patients.
    Eur J Haematol. 2018 Apr 6. doi: 10.1111/ejh.13073.
    PubMed     Text format     Abstract available


    J Clin Oncol

  7. WALTER RB
    Minimal Residual Disease Testing After Induction Chemotherapy for Acute Myeloid Leukemia: Moving Beyond Prognostication?
    J Clin Oncol. 2018 Apr 6:JCO2018783266. doi: 10.1200/JCO.2018.78.3266.
    PubMed     Text format    


    J Pediatr Hematol Oncol

  8. DE MATTEO A, Petruzziello F, Parasole R, Esposito A, et al
    Quantitative Ultrasound of Proximal Phalanxes in Childhood Acute Lymphoblastic Leukemia Survivors.
    J Pediatr Hematol Oncol. 2018 Apr 3. doi: 10.1097/MPH.0000000000001146.
    PubMed     Text format     Abstract available


    Leuk Lymphoma

  9. HUANG J, Hong M, Zhu Y, Zhao H, et al
    Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia.
    Leuk Lymphoma. 2018 Apr 4:1-10. doi: 10.1080/10428194.2018.1443328.
    PubMed     Text format     Abstract available

  10. KUROSAWA S, Toya T, Kishida Y, Nagata A, et al
    Outcome of patients with acute undifferentiated leukemia after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2018 Apr 4:1-4. doi: 10.1080/10428194.2018.1441410.
    PubMed     Text format    

  11. IMAGAWA J
    Switching from all-trans retinoic acid to arsenic trioxide for newly diagnosed acute promyelocytic leukemia.
    Leuk Lymphoma. 2018 Apr 4:1-3. doi: 10.1080/10428194.2018.1443333.
    PubMed     Text format    

  12. VAN DER STRATEN L, Dinmohamed AG, Westerweel PE, Langerak AW, et al
    Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy.
    Leuk Lymphoma. 2018 Apr 4:1-5. doi: 10.1080/10428194.2018.1452215.
    PubMed     Text format    

  13. ZHANG H, Liang Z, Hu Y, Wang X, et al
    The effectiveness of interferon-alpha combined with imatinib in patient with chronic myeloid leukemia harboring T315I BCR-ABL1 mutation.
    Leuk Lymphoma. 2018 Apr 4:1-2. doi: 10.1080/10428194.2018.1443329.
    PubMed     Text format    

  14. OJAMIES PN, Kontro M, Edgren H, Ellonen P, et al
    Case studies investigating genetic heterogeneity between anatomically distinct bone marrow compartments in acute myeloid leukemia.
    Leuk Lymphoma. 2018 Apr 4:1-4. doi: 10.1080/10428194.2018.1453067.
    PubMed     Text format    

  15. REDNER RL, Beumer JH, Kropf P, Agha M, et al
    A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia.
    Leuk Lymphoma. 2018 Apr 4:1-7. doi: 10.1080/10428194.2018.1443330.
    PubMed     Text format     Abstract available


    Leuk Res

  16. PEHLIVAN M, Caliskan C, Yuce Z, Sercan HO, et al
    Secreted Wnt antagonists in leukemia: A road yet to be paved.
    Leuk Res. 2018;69:24-30.
    PubMed     Text format     Abstract available

  17. LAM CF, Yeung HT, Lam YM, Ng RK, et al
    Reactive oxygen species activate differentiation gene transcription of acute myeloid leukemia cells via the JNK/c-JUN signaling pathway.
    Leuk Res. 2018;68:112-119.
    PubMed     Text format     Abstract available


    N Engl J Med


  18. More on Ofatumumab for TTP.
    N Engl J Med. 2018;378:1364-1365.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: